The startup Preventive, which is supported by investors such as Sam Altman, CEO of OpenAI, and Brian Armstrong, CEO of Coinbase, is covertly progressing with a 'gene-edited baby' initiative. This ambitious project is designed to avert genetic diseases by manipulating the DNA of human embryos. Already, a couple afflicted with genetic conditions has shown keen interest in being part of this groundbreaking endeavor. However, it's important to note that this technology is categorically prohibited in the United States, as well as in the majority of countries across the globe, due to substantial scientific and ethical concerns. At present, gene-editing technology remains in its nascent stages, with potential risks not yet thoroughly examined. Preventive is on a global quest to identify regions where embryo-editing research is permissible, with the UAE being one such potential location. In response to media inquiries, the company revealed that it has successfully raised $30 million in funding and has made a firm commitment not to proceed with human trials until absolute safety can be guaranteed.